Pfizer (PFE) reported an 8% growth in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015.
Pfizer (PFE) reported an 8% increase in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015.
Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016.
Sanofi’s Human Vaccines segment, Sanofi Pasteur, reported an 8.8% YoY rise in its 2016 revenues at 1.85 billion euros (~$1.98 billion).
Sanofi’s Diabetes and Cardiovascular segment’s revenues fell ~0.4% YoY at constant exchange rates to 7.8 billion euros (about $8.3 billion) in 2016.
Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.
Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.
Sanofi’s (SNY) 2016 revenues were mainly driven by Sanofi Genzyme and Sanofi Pasteur.
Sanofi’s top line has risen on rising sales in its Genzyme, Animal Health, and Vaccines segments.
Novartis (NVS) is currently involved in developing its investigational therapy SEG101 for sickle cell disease.
If LEE011 manages to demonstrate efficacy in difficult-to-treat cancer types, it could prove to be a major competitive advantage for Novartis.
Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.
Besides the concluded mammary oncology assessment of LEE011’s Efficacy and Safety-2 (or MONALEESA-2) trial, Novartis (NVS) is also exploring its investigational breast cancer therapy in other phase three trials.
Novartis (NVS) has been striving to differentiate its investigational oncology drug, LEE011, from other breast cancer drugs in three areas.
To fully utilize its technology, Novartis (NVS) has been extensively upgrading its core systems.
Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.
To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.
Novartis’s research and development strategy is based on portfolio prioritization, introducing cost efficiencies, implementing breakthrough technologies, and introducing new management.
In 2016, the surgical business of Alcon, Novartis’s (NVS) Consumables segment, witnessed a solid demand trend.
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.